Land: Sydafrika
Språk: engelska
Källa: South African Health Products Regulatory Authority (SAHPRA)
Lennon
A-LENNON DIAZEPAM 10 mg/2 mL SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): A-LENNON DIAZEPAM 10 mg/2 mL COMPOSITION: Each 2 mLampoule contains: Diazepam 10 mg Benzoate buffer 5% m/v Benzyl alcohol 1,5% v/v Ethanol 19,2% v/v PHARMACOLOGICAL CLASSIFICATION: A - 2.6: Tranquillisers PHARMACOLOGICAL ACTION: The effect of diazepam, a benzodiazepine, results from its action on the central nervous system i.e. sedation, hypnosis, decreased anxiety, muscle relaxation, anterograde amnesia and anticonvulsant activity. Elimination follows a biphasic pattern, with a rapid distribution phase, followed by a prolonged terminal elimination phase of 1 to 2 days. The half life of its principal metabolite, desmethyldiazepam, is 2 to 5 days. It is excreted in the urine. In addition to crossing the blood-brain barrier, diazepam and its metabolites also cross the placental barrier and is excreted in breast milk. INDICATIONS: Diazepam is used in the treatment of anxiety and tension states as a sedative and pre-medication, in the control of muscle spasm as in tetanus, in the management of alcohol withdrawal syndrome. It can also be used for the control of status epilepticus. Diazepam is only indicated when the disorder is severe, disabling or subjecting the individual to extreme stress. CONTRA-INDICATIONS: Diazepam is contraindicated in patients with known hypersensitivity to benzodiazepines. Caution should be taken when giving diazepam to patients with impaired liver, kidney or respiratory function. Elderly and debilitated patients are specially sensitive to its side-effects. Infants may be unable to metabolise diazepam. The effects of diazepam may be enhanced by alcohol, barbiturates, narcotics and other depressants of the central nervous system. Benzodiazepine Läs hela dokumentet